CorMedix Inc.是一家生物技术公司,专注于开发和商业化治疗和预防心血管疾病、代谢疾病、慢性肾病等领域的新型抗生素和其他治疗方案。该公司最新财报数据一经公布,股价随即出现近26%的大幅下跌。
财报显示,CorMedix在截至2024年1月1日的季度中,调整后每股亏损5美分,高于去年同期的每股亏损17美分,也未达分析师平均预期的每股亏损10美分。营收为1146万美元,虽然高于分析师预期的1084万美元,但整体经营状况并不理想。
分析人士指出,CorMedix此前经历了长期的业绩低迷和股价低迷,投资者原本对公司最新季度业绩有所期许。但实际财报数据未能符合预期,直接导致公司股价大幅下挫近26%。虽然营收数据有所超预期,但净亏损扩大的情况引发市场对公司前景的担忧,促使投资者纷纷抛售股票。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.